A Phase 3 interventional study of Pregabalin in Anxiety Neuroses, sponsored by Pfizer. Completed at 138 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2006-07-14.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 231 studies in Anxiety Disorders with a site in United Kingdom — 36 open to participants now, 38 under way, none of them phase 3. Anxiety Disorders · United Kingdom.
Among the 231 studies in Anxiety Disorders with a site in United Kingdom, this one is the 14th largest by enrollment of the 183 interventional ones that give a count, is one of 2 that started in 2001, is one of 7 in phase 3, and was the 3rd registered.
7,238 studies on the registry are indexed under Anxiety Disorders; 1,687 are open to participants now.
Browse Anxiety Disorders studies →36 of the 231 studies in Anxiety Disorders with a site in United Kingdom are open now. Recruiting first, the newest first:
Guy's and St Thomas' NHS Foundation Trust · Sites in United Kingdom
Ages 65+ · Healthy volunteers
King's College London · Sites in United Kingdom
Ages 18–60 · Healthy volunteers
Myota GmbH · Sites in United Kingdom
Ages 18–50
University of Reading · Sites in United Kingdom
Ages 60–80 · Healthy volunteers
University of Edinburgh · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 948 Anxiety Disorders studies recruiting now, 423 (45%) set no upper age limit and 457 (48%) stop at 75 or younger; 234 take children under 18; 321 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
231 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 9 · Phase 3 9 · Phase 4 3
First in 2001; this study’s year is marked. 2 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 511 is above the median of 80 across 6,092 interventional studies indexed under Anxiety Disorders.
Median enrollment 60 across the 183 interventional studies, 150 across the 47 observational. Of the 157 that completed or were terminated, 17 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 231 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 8 studies filed under Anxiety Disorders — fewer than ten, so there is no comparison to draw.
8 of the studies in Anxiety Disorders with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07872670NHS Highland Research, Development and Innovation OrganisationVirtual Reality Therapy to Improve Arthroplasty Outcomes | 2026-12-01 |
| NCT06604104University of EdinburghVisual Frailty in Ageing | 2027-01-11 |
| NCT07529886Guy's and St Thomas' NHS Foundation TrustSymptoms of Anxiety and/or Depression and SDM in Older Patients With CLTI | 2027-02 |
| NCT07466446University of EdinburghPost Intensive Care Accelerometery to Study and Support Recovery Outcomes | 2027-02-01 |
| NCT07135232Leeds Beckett UniversityThe Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health. | 2027-03-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 231 studies in Anxiety Disorders with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Determine long-term safety and tolerability of pregabalin in patients with anxiety disorders.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Safety Tolerability
Showing the first 100 of 138 sites across 14 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2001 and a completion of Mar 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin